AIM: To analyze the effect of calcium dobesilate combined with hypoglycemics for patients with diabetic retinopathy(DR)and cataract, and the influence on microcirculation of eye fundus, hypoxia inducible factor-1α(HIF-1α), vascular endothelial growth factor(VEGF)level.

METHODS: Totally 98 DR patients with cataract(126 eyes)from January 2013 to December 2015 in our hospital were selected as the research objects, and were divided into two groups randomly(treatment group: 64 eyes in 49 patients, control group: 62 eyes in 49 patients). The control group was treated with acarbose tablet and metformin, while treatment group was treated with calcium dobesilate additionally. The clinical effect, the glycemic control effect, serum HIF-1α and VEGF level, eye function and fundus microcirculation of two groups after 12mo were compared.

RESULTS: After 12mo, the total effective rates of two groups were 87.5%, 61.3% respectively, which indicated significantly difference(P<0.05); the vision of treatment group was significantly higher than that of control group(P<0.05). Two groups' blood glucose level decreased significantly, and no significant difference between two groups(P>0.05). After 1-month treatment, the plasma viscosity, erythrocyte aggregation index, erythrocyte deformability index, erythrocyte sedimentation rate and hematocrit in the treatment group were significantly lower than those in the control group(P<0.05). The PSV and EDV of the posterior ciliary artery and central artery in the treatment group were significantly higher than those in the control group(P<0.05), and RI was significantly lower than that in the control group(P<0.05). After 12-month treatment, the HIF-1α level of two groups were 35.90±11.36mmol/L, 46.75±12.08mmol/L respectively; the VEGF of two groups level were 89.72±13.61mmol/L, 110.30±16.74mmol/L, respectively, the treatment group's HIF-1α level and VEGF were significantly lower than control group(P<0.05), and both decreased significantly after treatment(P<0.05).

CONCLUSION: Calcium dobesilate combined with hypoglycemics can effectively increase the clinical effect in the treatment of retinopathy diabetic cataract, effectively control blood glucose, improve microcirculation of eye fundus, decrease HIF-1α, VEGF level, inhibit angiogenesis.